RxDoctor Payments Data

Kristin Stalker

Family · Albany, NYNPI 1326504234

Payments from drug & device makers

$1,825in general payments, 2019–2025

Across 68 payments — averaging $26.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$373
  • Boston Scientific$245
  • Myriad Genetic Laboratories, Inc.$203
  • AstraZeneca$133
  • Genmab U.S., Inc.$125
  • Seagen Inc.$100
  • plus $646 from 14 others

What the payments were for

  • Food & beverage$1,72595%
  • Education$1005%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,825 in reported general payments places this provider in the 80th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$47,554
Medicare patients
104
Services billed
1,455

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZejulaNiraparib Tosylate20$490,871
LynparzaOlaparib16$221,511
YuvafemEstradiol28$4,938
Estradiol31$4,156
Pregabalin39$1,646
Clobetasol Propionate21$567
Gabapentin21$365
Ondansetron OdtOndansetron20$328
Dexamethasone30$290
Prochlorperazine Maleate24$276
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst21$236
Letrozole19$200
Metronidazole12$197
Oxycodone Hcl18$185
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav14$115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKZejula$21$490,87120 claims
AstraZenecaLynparza$133$221,51116 claims
Lilly USA, LLCOlanzapine$24$10515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,883 family providers in New York.

Other family in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →